Growth in Global Antibacterial Drugs Market Limited to 1.30% CAGR Owing to Patent Expiries19 Jan 2016
Rise in drug resistant species, launch of generics, and upcoming patent expirations during the period of 2015 to 2023 is likely to hamper the growth of the global antibacterial drugs market, states Transparency Market Research in its latest report. The 150-page research publication, titled “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023”, indicates that registering a poor CAGR of 1.30% during the forecast period, the worldwide market for antibacterial drugs in projected to drop from US$43.9 Bn in 2014 to US$38.9 Bn by 2023.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Antibacterial drugs are categorized into eight major classes: tetracyclines, β-Lactams, phenicols, macrolides, quinolones, aminoglycosides, sulfonamides, and miscellaneous antibacterials. Accounting for a 58% share in 2014, β-Lactams dominated the overall antibacterial drugs market. While quinolones held a 17% share that same year, this class of drugs is anticipated to register negative CAGR by the end of 2023. Growing geriatric population and rising demand for therapies against bacterial infections is likely to boost the miscellaneous antibacterials segment.
The strong pipeline in the antibacterial drugs market comprises Omadacycline (PTK-0796), SYM-1219, Zempia (E-101), Delamanid, Ozenoxacin, SPL7013, Eravacycline, Actoxumab / Aezlotoxumab (MK-3415A), Solithromycin (CEM-101), Ciprofloxacin/Fluocinolone Acetonide, Arikace, Carbavance (meropenem/RPX7009), RHB-105, Delafloxacin, Surotomycin (MK-4261), Cadazolid, and Plazomycin. Future commercialization of these antibacterial drugs is projected to boost the global market.
Geographically, the global antibacterial drugs market is segmented into North America, Asia Pacific, Latin America, Europe, and Rest of the World. Asia Pacific presently dominates the overall market and is also projected to witness the fastest growth over the duration of the forecast period. The Asia Pacific antibacterial drugs market is fueled by rising incidences of bacterial infections such as tuberculosis and MRSA, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, rising purchasing power of the domestic population, expanding geriatric population, and developing healthcare infrastructure.
North America, followed by Europe, is the second largest regional market for antibacterial drugs in terms of revenue. These regions are anticipated to witness slow growth over the next seven years owing to stringent regulatory requirements, shortened product lifecycle, and generic infiltration.
The research report identifies and assesses the performance of the key players operating in the global antibacterial drugs market. These players are profiled based on attributes such as company and financial overview, business strategies, product portfolio, and recent developments. The companies featured in the antibacterial drugs market report are GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, AstraZeneca plc, Allergan plc (Actavis Plc), Bayer AG, and Eli Lilly and Company.
Global Antibacterial Drugs Market, by Drug Class
Request For Free Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY - 12207